TABLE 2.

Primary and secondary outcomes

Outcome by type	Value for the groupc		P value
	MEM+VAN (n = 338)	TZP+VAN (n = 9,898)
Primary outcomes (no. of patients [%])
AKI	52 (15.4)	2,713 (27.4)	<0.001
Risk	33 (9.8)	1,516 (15.3)	0.006
Injury	12 (3.5)	777 (7.8)	0.005
Failure	7 (2.1)	420 (4.2)	0.068
Secondary outcomes
Inpatient mortality (no. of patients [%])	35 (10.3)	1,144 (11.6)	0.552
No. of days of hospitalization (median [IQR])a	9 (6–15)	10 (5–18)	0.482
AKI recovery (no. of patients [%])b	31 (59.6)	1276 (47.0)	0.097

^aIQR, interquartile range.

^bPercentages represent patients with AKI in the treatment group.

^cMEM, meropenem; TZP, piperacillin-tazobactam; VAN, vancomycin.